Skip to content

Efficacy and safety analysis of bupivacaine liposomes for ultrasound-guided posterior lumbar muscle block for postoperative analgesia in laparoscopic hysterectomy

Efficacy and safety analysis of bupivacaine liposomes for ultrasound-guided posterior lumbar muscle block for postoperative analgesia in laparoscopic hysterectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104249
Enrollment
Unknown
Registered
2025-06-13
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperation pain

Interventions

Control group: ropivacaine group (R group: 60mL of 0.25% ropivacaine hydrochloride):Ultrasound guided bilateral posterior lumbar muscle block
Experimental group: bupivacaine liposome group (LB group: LB20mL+physiological saline 40mL):Ultrasound guided bilateral posterior lumbar muscle block

Sponsors

Panzhihua Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
19 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Age range of 19-70 years old; 2.Body mass index (BMI) 18-28kg/m^2; 3.American Society of Anesthesiologists (ASA) grades I-II; 4.Patients who are able to understand and willing to use VAS scoring to report pain.

Exclusion criteria

Exclusion criteria: 1.Patient refusal; 2.For individuals with contraindications to regional anesthesia; 3.Individuals who are allergic to the drugs used during anesthesia; 4.Long term use of opioid drugs, sedatives, antidepressants, monoamine oxidase inhibitors, and other medications; 5.Whole body or puncture site infection; 6.Abnormal coagulation time and platelet count; 7.Severe preoperative complications (severe hypertension, heart failure, severe arrhythmia, severe lung disease, severe liver and kidney dysfunction, digestive ulcers, mental or neurological disorders, cognitive impairment); 8.Previous chronic pain; 9.Language communication barriers; 10.Follow up failed or dropped out midway.

Design outcomes

Primary

MeasureTime frame
The number of presses on the analgesic pump; Postoperative sufentanil consumption; The utilization rate of additional flurbiprofen ester in the ward;;

Secondary

MeasureTime frame
First time of getting out of bed activity;Surgical duration;Patient satisfaction score;hospital stay;Incidence of postoperative complications;QLB onset time;Total amount of opioid drugs during surgery;;VAS scores during rest and exercise at 4, 8, 12, 24, 48, and 72 hours postoperatively;

Countries

China

Contacts

Public ContactBangjian Zhang

Panzhihua Central Hospital

376243940@qq.com+86 18096307256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026